Lunit

Lunit 2026 Annual General Meeting 📊 Lunit successfully held its Annual General Meeting on March 31, bringing together shareholders to review the company’s direction. The reappointment of Anthony Paek as Chair reinforces continuity in leadership and reflects our commitment to stable governance and long-term execution. With a consistent leadership foundation in place, we remain focused on advancing AI into real-world clinical practice and delivering meaningful impact in healthcare. 🔗 Explore more about Lunit’s investor information: www.lunit.io/en/investors

🌍 Lunit at the World Economic Forum 2026 In January 2026, Lunit will take part in the World Economic Forum Annual Meeting in Davos for the fourth consecutive year, participating as an Associate Partner. Over the past three years, Lunit has engaged with global leaders around some of the world’s most pressing questions including cooperation in a more contested world, unlocking new sources of growth, and the responsible deployment of emerging technologies. This year’s Forum brings together leaders from business, government, civil society, and the scientific community to explore how dialogue, collaboration, and innovation can shape a more resilient future. As a medical AI company, Lunit contributes perspectives on how responsible AI, evidence-based deployment, and data-driven healthcare can deliver real-world clinical impact  from earlier cancer detection to stronger and more sustainable healthcare systems. As a WEF Associate Partner, Lunit will continue to engage in dialogue and collaboration with global stakeholders in Davos. 🔗 Learn more about Lunit’s vision for global healthcare and AI : www.lunit.io/en 📄 Read the full press release: https://lnkd.in/gXRpvJkf  #Lunit #WEF2026 #Davos #HealthcareAI #MedicalAI #ResponsibleAI #GlobalHealth

🤝 We’re excited to announce our new collaboration with Daiichi Sankyo US to advance AI-powered digital pathology research and diagnostics in oncology! The collaboration is to leverage Lunit SCOPE IO and SCOPE universal IHC (uIHC) digital pathology in two Daiichi Sankyo research and development programs. Daiichi Sankyo will apply various Lunit SCOPE solutions to explore novel biomarkers, enrich clinical trials, or to potentially support precision patient stratification for oncology pipeline programs. 📢 Click to read the full announcement! https://lnkd.in/eyThtZWe #DaiichiSankyo #LunitOncology #DigitalPathology

🔍  Introducing Lunit INSIGHT Risk — our image-based breast cancer risk prediction model. Lunit has submitted a 510(k) application to the U.S. FDA for Lunit INSIGHT Risk, our image-based breast cancer risk prediction model, originally developed at Washington University School of Medicine in St. Louis by Dr. Graham Colditz and Dr. Shu Joy Jiang, and later acquired by Lunit. While this regulatory milestone is significant, what matters even more is the shift this technology can help bring to the future of breast cancer screening. With the FDA recently authorizing the first AI platform for breast cancer risk prediction in the U.S., momentum behind risk-based screening is accelerating—signaling a meaningful pathway for bringing image-derived risk prediction into routine clinical practice. What sets Lunit INSIGHT Risk apart is its image-only approach, estimating a woman’s five-year breast cancer risk directly from routine mammography or DBT images—without questionnaires or genetic tests. The model’s outputs are also SEER-calibrated, aligning five-year absolute risk scores with U.S. disease incidence rates to support clinically meaningful decision-making. Lunit INSIGHT Risk received FDA Breakthrough Device Designation and participates in the FDA TAP program, helping ensure the model’s readiness for real-world adoption and regulatory review. As screening programs shift toward more personalized and risk-informed pathways, image-based risk estimation provides a scalable and clinically grounded foundation for the next era of breast cancer prevention. This submission represents more than a filing—it reflects Lunit’s commitment to advancing evidence-based, risk-stratified screening worldwide. We will continue working to make personalized breast cancer prevention more accessible, more actionable, and more impactful for women and health systems everywhere. 🔗 Full press release: https://lnkd.in/gcmKQ3ay 🔗 Interview with Dr. Graham Colditz: https://lnkd.in/gYTXbjFC #Lunit #LunitINSIGHTRisk #ImageBasedRisk #CancerScreening #MedicalAI #RadiologyAI #FDA

🚀RSNA 2025: Lunit’s Evidence Momentum Continues Thank you for joining us at Radiological Society of North America (RSNA) 2025. At this year’s meeting, we presented one of Lunit’s most extensive and rigorously validated evidence portfolios to date — 14 studies spanning screening mammography, DBT, breast density, and risk modeling. Across 193,000+ real-world screening exams, 1,000 DBT cases, and 335,000+ longitudinal density images, we reinforced a clear message: evidence-driven AI meaningfully elevates accuracy, consistency, and risk-adapted screening around the world. From Capio S:t Göran (Sweden), we shared real-world findings showing that AI-supported single reading improved invasive cancer detection, increased PPV, and reduced unnecessary recalls compared to human-only double reading — further supporting results from the ScreenTrustCAD trial. In a study conducted by Massachusetts General Hospital, we showcased new data demonstrating that Lunit INSIGHT DBT localized 84.4% of true-positive cancers, while providing valuable insights into strengths and subtype-specific limitations as DBT adoption continues to expand worldwide. We also highlighted research from Elizabeth Wende Breast Care, where volumetric breast density, as quantified by AI-powered algorithms, and multi-year density trends significantly improved prediction accuracy, strengthening the foundation for personalized, risk-adapted care. Throughout the week, we brought global leaders together in our Education Room to discuss image-based risk, interval cancer detection, academic adoption, and real-world DBT performance — reflecting a growing commitment to transparent, clinically validated AI across the radiology community. RSNA remains a key stage where the field looks to confirm whether AI is delivering measurable clinical value. We are grateful to everyone who visited our booth, participated in our sessions, and shared their insights with us. Read the full press release: 🔗 https://lnkd.in/gfsZ6dw5 Learn more about Lunit’s solutions: 🌐 https://www.lunit.io/en Explore more RSNA updates: 🔗 https://lnkd.in/gYTXbjFC #RSNA2025 #Lunit #BreastAI #MMG #CancerScreening #DBT #AIinHealthcare #MedicalImaging #PrecisionOncology #Radiology

🔍 SimonMed Imaging is leading one of the industry’s first large-scale custom foundation model deployments—powered by Lunit’s Foundation Model Services (FMS) As one of the largest outpatient imaging providers in the U.S., SimonMed is taking a landmark step forward—building a fully custom chest X-ray report-generation model on Lunit’s multimodal foundation models. This represents one of the earliest and most ambitious clinical deployments of foundation models in radiology. Through Lunit’s Foundation Model Services (FMS), SimonMed is fine-tuning the model with its own imaging data and reports, creating AI that reflects its real patient population, reporting patterns, and clinical workflows. This institution-specific approach goes far beyond traditional AI deployments—enabling performance that is smarter, more consistent, and deeply aligned with how radiologists work every day. By leveraging foundation models trained on vast multimodal datasets, FMS addresses one of the most persistent challenges in medical AI: performance variability across sites. With ongoing self-learning and refinement, these models continue to improve over time setting a new benchmark for scalable, clinically meaningful AI in imaging. This collaboration marks a major milestone not only for Lunit and SimonMed, but for the global medical AI landscape. Large-scale, custom foundation model implementations remain extremely rare, and this initiative establishes a new direction for how AI will be built and deployed across the world’s hospitals and imaging networks. As we expand our multimodal foundation model portfolio, Lunit will continue driving the next era of AI-powered radiology adaptive, reliable, and built for real clinical practice. 📄 Read the full press release: https://lnkd.in/e22qwyV3 #Lunit #SimonMed #FoundationModels #FMS #MedicalAI #RadiologyAI #HealthcareInnovation

✨ Lunit Heatmap: Visualizing Our Vision The Lunit Heatmap is more than a design element. It represents the moment when what was once hard to see becomes clear the starting point of insight that leads to better decisions in cancer care. Inspired by the diagnostic maps used in clinical practice, this visual language reflects a meaningful progression: from detection to understanding, from clarity to possibility. With our renewed brand identity, the Heatmap remains a foundational expression of who we are. By illuminating information and highlighting key patterns, it reflects our commitment to enabling more accurate and consistent decisions for clinicians and researchers around the world. Building on this vision, Lunit will continue to elevate the standards of AI-powered cancer diagnosis and precision oncology, advancing our mission to Conquer Cancer Through AI. 👉 Learn more about our mission and unified brand identity: 🏠 Explore the new unified website: https://www.lunit.io/en/ 📄 Read the full press release: https://lnkd.in/e8d_ZrWA #Lunit #LunitBrand #LunitHeatmap #BrandIdentity #VisualIdentity #HealthTech #AIinHealthcare #DigitalHealth #CancerCare #ConquerCancerThroughAI

🔬 Mapping the Tumor–Immune Landscape with AI | Lunit at SITC 2025 At the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2025), Lunit presented three new studies showcasing how our AI-powered Lunit SCOPE® suite is advancing digital pathology and precision oncology. Among the studies, in collaboration with CellCarta, Lunit demonstrated that AI can standardize immune phenotyping across tumor types and accelerate antibody-based drug discovery—bridging research insights with real-world clinical practice. Together, these studies highlight how Lunit SCOPE IO and Lunit SCOPE uIHC help researchers understand the tumor–immune microenvironment, revealing new pathways for immunotherapy and antibody targets. We successfully concluded our participation at SITC 2025, strengthening global collaboration and highlighting how AI continues to transform precision oncology. 🔎 Learn more about our work at SITC 2025: https://lnkd.in/ekqNSi9s 📄 Read the full press release: https://lnkd.in/gxgb7SpK #Lunit #SITC2025 #AIinHealthcare #AIBiomarker #PrecisionOncology #Immunotherapy #CellCarta #LunitSCOPE

Lunit and Volpara Unite Under One Name 'Lunit' — A New Chapter Begins 💫 We’re proud to announce that Volpara Health Technologies has officially joined the Lunit brand — coming together as one name, one mission. This integration marks the beginning of a new era in AI-powered cancer care — uniting our strengths to cover the full cancer continuum, from breast health and risk assessment to cancer screening and precision oncology. Where data meets discovery, and innovation meets hope — Lunit will continue advancing our mission to conquer cancer through AI. For more details about the rebranding and to watch the full video, visit our pages: Lunit Cancer Screening(https://lnkd.in/eRzvchSf) Lunit Oncology(https://lnkd.in/gZtJdGwS) 🏠 Explore the new unified website: www.lunit.io/en 📄 Read the full press release: https://lnkd.in/e8d_ZrWA #Lunit #Volpara #Rebranding #MedicalAI #CancerIntelligence #AIinHealthcare #PrecisionMedicine #HealthcareInnovation #GlobalHealth #BrandIntegration

🏛 Lunit Showcases the Future of Korean Medical AI at the APEC 2025 Advanced Industries Hall At the Advanced Industries Hall, held during APEC 2025 KOREA, Lunit proudly participated as a representative of Korea’s medical AI innovation. As one of the key exhibitions introducing next-generation industries from across the Asia-Pacific region, this event was a truly meaningful opportunity for us to share our vision with the world. As the only Korean medical AI company featured in the exhibition, Lunit showcased how artificial intelligence can transform the future of cancer diagnosis and revolutionize the field of life sciences. We were deeply honored to welcome Kim Min-seok, Prime Minister of Korea; Kristalina Georgieva, Managing Director of the IMF; and Paul Grimes, CEO of Austrade(Australian Trade and Investment Commission), among other distinguished guests, who visited our booth to experience our AI-powered cancer screening solution, Lunit INSIGHT. More than a showcase, our participation at APEC 2025 symbolizes Lunit’s broader commitment—to elevate Korea’s global leadership in medical AI and to advance our mission, “Conquer Cancer through AI.” Lunit will continue to develop AI solutions that make a real impact on patients’ lives and further solidify Korea’s standing as a leader in medical technology. 🌍 #Lunit #APEC2025 #AIinHealthcare #FutureTech #MedicalAI #KoreaInnovation #ConquerCancerThroughAI